Toxic profile of benznidazole in patients with chronic chagas disease: Risk factors and comparison of the product from two different manufacturers

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6125-6131

  Molina, I ^a   Salvador, F ^a   Sanchez Montalva A ^a   Trevino B ^a   Serre, N ^a   Avilés, A Sao ^a   Almirante, B ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BENZNIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

ADULT; AGE; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; CHAGAS DISEASE; CHRONIC DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATITIS; DESQUAMATION; DIGESTIVE SYSTEM DISEASE; DISEASE DURATION; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG WITHDRAWAL; DYSGEUSIA; EOSINOPHILIA; EPIGASTRIC PAIN; ERYTHROMELALGIA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MUCOSAL DRYNESS; NAUSEA AND VOMITING; NEUTROPENIA; OBSERVATIONAL STUDY; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RISK FACTOR; SEX DIFFERENCE; SKIN DISEASE; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; MIDDLE AGED;

ADULT; CHAGAS DISEASE; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84942914027     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04660-14     Document Type: Article

References (19)

1. Chagas C, Chagas C. 1909. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1:159-218. http://dx.doi.org/10.1590/S0074-02761909000200008.
2. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. 2007. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298:2171-2181. http://dx.doi.org/10.1001/jama.298.18.2171.
3. Bern C. 2011. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 364:2527-2534. http://dx.doi.org/10.1056/NEJMct1014204.
4. Hasslocher-Moreno AM, do Brasil P E AA, de Sousa AS, Xavier SS, Chambela MC, Sperandio da Silva GM. 2012. Safety of benznidazole use in the treatment of chronic Chagas' disease. J Antimicrob Chemother 67:1261-1266. http://dx.doi.org/10.1093/jac/dks027.
5. Rassi A, Jr, Rassi A, Marin-Neto JA. 2010. Chagas disease. Lancet 375:1388-1402. http://dx.doi.org/10.1016/S0140-6736 (10) 60061-X.
6. Pinazo M-J, Muñoz J, Posada E, López-Chejade P, Gállego M, Ayala E, del Cacho E, Soy D, Gascon J. 2010. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 54:4896-4899. http://dx.doi.org/10.1128/AAC.00537-10.
7. Riera C, Verges M, Iniesta L, Fisa R, Gállego M, Tebar S, Portús M. 2012. Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera. Am J Trop Med Hyg 86:412-416. http://dx.doi.org/10.4269/ajtmh.2012.11-0111.
8. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A. 2009. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 7:157-163. http://dx.doi.org/10.1586/14787210.7.2.157.
9. Castro JA, de Mecca MM, Bartel LC. 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 25:471-479. http://dx.doi.org/10.1191/0960327106het653oa.
10. Cancado JR. 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop São Paulo 44:29-37.
11. Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faúndez M, Galanti N, Ferreira A, Morello A. 2007. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146:601-620. http://dx.doi.org/10.1016/j.cbpa.2006.03.004.
12. Tornheim JA, Lozano Beltran DF, Gilman RH, Castellon M, Solano Mercado MA, Sullca W, Torrico F, Bern C. 2013. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl Trop Dis 7:e2407. http://dx.doi.org/10.1371/journal.pntd.0002407.
13. De Pontes V M O, de Souza Júnior AS, da Cruz F M T, Coelho H L L, Dias A T N, Coêlho I C B, de Oliveira, MF. 2010. Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará. Rev Soc Bras Med Trop 43:182-187. http://dx.doi.org/10.1590/S0037-86822010000200015.
14. Carrilero B, Murcia L, Martínez-Lage L, Segovia M. 2011. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Rev Esp Quimioter Publ Soc Esp Quimioter 24:123-126.
15. Pinazo M-J, Guerrero L, Posada E, Rodríguez E, Soy D, Gascon J. 2013. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease. Antimicrob Agents Chemother 57:390-395. http://dx.doi.org/10.1128/AAC.01401-12.
16. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. 2007. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40:1-10. http://dx.doi.org/10.1590/S0037-86822007000100001.
17. Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A. 2014. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 370:1899-1908. http://dx.doi.org/10.1056/NEJMoa1313122.
18. Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, Ruiz Vera B, Vigliano C, de Rissio AM, Segura EL. 2004. Treatment of Chagas disease with benznidazole and thioctic acid. Medicina 64:1-6. (In Spanish.)
19. Altcheh J, Moscatelli G, Mastrantonio G, Moroni S, Giglio N, Marson ME, Ballering G, Bisio M, Koren G, García-Bournissen F. 2014. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 8:e2907. http://dx.doi.org/10.1371/journal.pntd.0002907.